lung cancer
MSD’s Keytruda impresses in lung cancer chemotherapy trial
December 21, 2015Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab
MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …
NICE rejects BMS cancer drug in draft guidance
December 16, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo
In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
Roche lung cancer drug Alecensa gets rapid US approval
December 14, 2015Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer
The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …
Early UK access for AstraZeneca lung cancer drug
December 9, 2015AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib
UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
Pfizer lung cancer treatment gets expanded EU approval
December 1, 2015Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer
Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …
Lilly cancer drug gets US approval
November 26, 2015NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology
Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …
AstraZeneca earns ‘speedy’ FDA approval for lung cancer drug
November 13, 2015AZD9291, AstraZeneca, Tagrisso, lung cancer
The FDA has approved AstraZeneca’s new lung cancer drug Tagrisso, in a record two and half years from development, under …
Merck and Pfizer begin new Phase III avelumab trial in lung cancer
November 5, 2015Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer
Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …
AstraZeneca halts lung cancer trials amidst safety concerns
October 13, 2015Manufacturing and Production AZD9291, AstraZeneca, MEDI4736, NSCLC, drug safety, durvalumab, interstitial lung disease, lung cancer, non-small cell lung cancer
AstraZeneca is stopping two trials of a combination of two of its pipeline cancer treatments, after reports that the pairing …
FDA approves Merck’s Keytruda for advanced NSC lung cancer
October 5, 2015Research and Development, Sales and Marketing BMS, NSCL, keytruda, lung cancer, merck sharp and dohme, opdivo
The US Food and Drug Administration has granted accelerated approval for Merck’s Keytruda (pembrolizumab) to treat patients with advanced (metastatic) …
Genetic study reveals new associations with lung disease and smoking behaviour
September 25, 2015Medical Communications, Research and Development COPD, lung cancer, smkoing
New research published in The Lancet Respiratory Medicine and presented at this year’s European Respiratory Society (ERS) Congress in Amsterdam …
AstraZeneca lung cancer drug clears UK market access hurdle
September 4, 2015Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer
Follow @Pharmafocus
Lilly defeats Teva in US court over Alimta patent
August 26, 2015Research and Development, Sales and Marketing Alimta, Eli Lilly, Teva Pharmaceutical, lung cancer
Eli Lilly has won a case in a US federal court, in a battle over Teva’s attempt to create a …
Roche lung cancer therapy succeeds in mid-stage trial
August 17, 2015Research and Development, Sales and Marketing Genentech, Roche, atezolizumab, lung cancer, non-small cell lung cancer
Roche’s biotech arm Genentech has scored positive results in a pivotal Phase II study of its investigational cancer immunotherapy atezolizumab. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
